AAAnna V. Abramchenko

Anna V. Abramchenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna V. Abramchenko has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Gamma interferon in patients with drug-resistant pulmonary tuberculosis: clinical and cost-effectiveness aspects

    by A. G. Samoilova, I. A. Burmistrova, A. I. Gaida, A. V. Abramchenko, M. I. Romanova, V. V. Ryazhenov

    Objective : To evaluate the efficacy of gamma interferon (IFN-γ) injections for patients with multidrug-resistant tuberculosis (MDR-TB) undergoing antituberculosis chemotherapy according to current clinical guidelines through a clinical and economic analysis. Material and methods . A clinical-economic model of the two strategies for managing MDR-TB patients was developed. The costeffectiveness of these strategies was determined taking into account only the direct costs of inpatient care. Time-based costs for patient management were calculated, focusing on the period from the start of therapy to the end of the study drug administration (3 months). This included: Period 0 – the start of therapy, days 1–14 plus 3 days for testing to confirm the absence of bacterial excretion; Period 1 – days 18–30 + 3 days for testing; Period 2 – days 34–60 + 3 days for testing; Period 3 – days 64–90 + 3 days for testing. For budget impact analysis we used the difference in costs between the two treatment strategies: antituberculosis chemotherapy with IFN-γ injections (the main group) and antituberculosis chemotherapy without IFN-γ (the control group). Efficiency parameters included sputum conversion rates based on microscopy and the median time to clinical response. Cost-effectiveness ratios were calculated using the clinical efficiency of the compared therapies, taking into account sputum smear conversion rates based on microscopy. The results were verified using a one-factor sensitivity analysis based on the cost-effectiveness ratio within a range of ±30%. Results . Pharmacotherapy costs during the first 14 days of hospitalization were higher in the group treated with IFN-γ (12,347,287.00 rubles) compared with the control group (10,723,532.00 rubles). Due to the clinical response achieved, a significantly larger number of patients in the main group are transferred to outpatient care, and costs in Period 1 for this group tend to decrease (1,394,517.12 rubles), while in the control group they are three times higher (4,138,021.76 rubles). Costs in the control group were 3.8 times higher than in the main group in Period 2, and 3.3 times higher in Period 3. Total costs for inpatient care over the 3-month treatment period with the study drug (the main group) were 1.5 times lower than those in the control group. Furthermore, the results were supported by calculations using the time to clinical response, as determined by microscopic examination. These calculations showed that the treatment in the main group was 25.64% more cost-effective than in the control group. The lower cost-effectiveness ratio in the main group compared to the control group (1,401.51 and 1,802.27, respectively) and the higher clinical efficacy in terms of the main criterion indicate that including IFN-γ in the treatment of MDR-TB patients is more cost-effective and preferable. A one-factor sensitivity analysis based on the cost-effectiveness metric confirmed the robustness of the findings to uncertainties and variations in the input data. Conclusion . The results obtained indicate the economic feasibility of adding IFN-γ as a pathogenetic therapy for MDR-TB in combination with antituberculosis chemotherapy.

  • Open Access

    Searching for Ideal Oxazolidinone for Treatment of Tuberculosis

    by A. I. Gayda, G. N. Mozhokina, E. R. Pereverzeva, M. I. Romanova, A. V. Abramchenko, A. G. Samoylova

    Oxazolidinones represent a promising class of drugs for treatment of multidrug-resistant tuberculosis (MDR-TB). Linezolid, the first representative of this class, is highly effective; however, its use is limited due to its toxicity (myelosuppression, neuropathy). 63 publications were analyzed in order to search for new oxazolidinones for treatment of tuberculosis. New drugs and compounds (tedizolid, sutezolid, contezolid, delpazolid, and TBI-223) have a more favorable safety profile with antimycobacterial activity similar to or even greater than that of linezolid. In the coming years, these compounds may become an important component of short, safe, and effective chemotherapy regimens for tuberculosis.

  • Open Access

    Effectiveness and Safety of Recombinant Interferon Gamma in the Treatment of Drug-Resistant Respiratory Tuberculosis

    by M. I. Romanova, A. V. Abramchenko, A. I. Gayda, G. N. Mozhokina, A. G. Samoylova, I. A. Vasilyeva

    The objective : to evaluate the effectiveness and safety of recombinant interferon gamma in the combination therapy of drug-resistant pulmonary tuberculosis. Subjects and Methods . 84 patients with drug-resistant tuberculosis were enrolled in the study, who were randomized equally into two groups: Main Group (MG) and Control Group (CG). In both groups, patients received anti-tuberculosis chemotherapy in accordance with the individual drug susceptibility of Mycobacterium tuberculosis. Patients in MG additionally received recombinant interferon gamma (rIFN-γ) (intramuscularly, 500,000 IU once a day daily for 3 months). The patients were followed up for 6 months. Results. During treatment in the patients from both groups, clinical manifestations of tuberculosis decreased, but in MG this occurred faster. In MG, sputum conversion was reported on average after 18.6 days of treatment (by smear) and 16.8 days (by culture) versus 28.8 days and 25.5 days, respectively, in the CG (p0.05). A total of 87 AEs were reported: in 48 patients in MG and in 39 patients in CG. The majority of patients developed 1-2 AEs. The most common AEs were abnormal laboratory rates. In all patents from MG, the tolerability of rIFN-γ was assessed as excellent. The study revealed that rIFN-γ as a 3-month course in addition to anti-tuberculosis chemotherapy could shorten the treatment time and improve effectiveness of treatment in patients with drug-resistant tuberculosis.


  • Open Access

    ENT organ tuberculosis in the practice of a pediatrician: A retrospective study

    by Olga K. Kiselevich, Elena Y. Radtsig, Maria G. Kobulashvili, Anna V. Abramchenko, Milana A. Batchaeva, Svetlana V. Chegarnova

    Background. Despite a decline in the overall incidence of tuberculosis, the diagnosis and treatment of extrapulmonary forms remain challenging. The rarity of these manifestations, combined with limited clinician awareness, reduces pediatricians' and related specialists' vigilance, hindering timely detection. Diagnosis of extrapulmonary forms of the disease is difficult due to their oligobacillary nature and the difficulty of obtaining samples suitable for culture and molecular genetic confirmation. Extrapulmonary localizations of tuberculosis are secondary manifestations of the disease. When pulmonary forms are detected, the possibility of concomitant involvement of other organs and systems is often underestimated. In the Russian and international literature, single clinical cases of ENT organ tuberculosis are presented, mostly in the context of the development of generalized severe forms. Aim. To actualize the problem of ENT organ tuberculosis in children, drawing the attention of specialists to its clinical importance, despite the overall decrease in the incidence of tuberculosis. Materials and methods. A retrospective review of medical records from 668 patients aged 0 to 3 years who were treated in the therapeutic pulmonary pediatric department of the Moscow Research and Clinical Center for Tuberculosis Control over the past 15 years was conducted. Results. ENT organ tuberculosis was diagnosed in 10 children (1.5% of the cohort). Patient ages ranged from 1 month 21 days to 1 year 9 months (mean 12 ± 1.85 months), with nearly twice as many boys as girls (7 boys, 4 girls). All patients exhibited generalized disease: one patient (0.15%) had involvement of two organs, six patients (0.9%) had involvement of three organs, and, in rare cases (0.15% each), four or five organs were involved. Contact with a tuberculosis patient was identified in seven children (1.05%), with the mother as the source in five cases (0.07%) (including two mothers with concurrent HIV infection) and other relatives (father, uncle) in two cases. The source of infection was not identified in three patients. BCG-M vaccination was given to 6 children (0.9% of the total sample); the remaining patients had a medical exemption or parental refusal. Middle ear involvement was the most common clinical manifestation, observed in seven patients (1.05% of the total sample and 70% of the group with ENT organ tuberculosis), and was mainly complicated by anthritis or mastoiditis in four patients (0.6% of the total sample and 40% of the group with ENT organ tuberculosis). In the remaining three cases, tuberculosis of the larynx and pharynx was detected. Conclusion. Suspicion of tuberculosis necessitates a comprehensive evaluation, including a detailed history of BCG vaccination, contact with tuberculosis patients, and risk factors, as well as follow-up monitoring of disease progression, radiographic findings, and immunodiagnostic testing. Diagnosis of ENT tuberculosis should be established as early as possible, ideally within one month of symptom onset. It is essential to obtain samples for morphological analysis, assess the rate of tissue destruction, and determine the sequence of structural involvement in the pathological process. It is necessary to promptly include tuberculosis in the differential diagnosis, especially in cases of slowly progressing lesions of any localization that are not responding to standard treatment.

  • Open Access

    Effectiveness and Safety of Tauractant in the Treatment of Drug-Resistant Respiratory Tuberculosis

    by A. I. Gayda, A. G. Samoylova, M. I. Romanova, A. V. Abramchenko, O. V. Lovacheva, I. A. Vasilyeva

    The objective: to evaluate effectiveness and safety of inhaled highly purified tauractant as a pathogenetic agent in the treatment of pulmonary tuberculosis with multiple, pre-extensively and extensively drug resistance.Subjects and Methods. 104 patients with drug-resistant tuberculosis were included in the study, 29 of them were HIV-positive. Patients received chemotherapy (CT) according to the regimen for drug-resistant tuberculosis (MDR, pre-MDR, and MDR) based on the individual drug susceptibility of Mycobacterium tuberculosis (MTB). Tauractant was administered by inhalation in the form of a lyophilisate for the emulsion preparation. The patients were randomized into 2 groups: In CT+ST Group (n=52), surfactant therapy was prescribed in addition to chemotherapy, using tauractant in the form of Surfactant BL (Russia) at a dose of 25 mg according to the regimen [5], in CT Group (n=52), only chemotherapy was administered.Results. By the end of 2 months of chemotherapy, respiratory symptoms resolved in 35/39 (89.7%) patients in CT+ST Group, and in 22/33 (66.7%) in CT Group (p<0.05). Positive X-ray changes were observed in 39/52 (75.0%) patients in CT+ST Group and in 28/52 (53.8%) patients in CT Group, (p<0.05), and healing of cavities was observed in 9/30 (30.0%) and 2/33 (6.1%) (p<0.05) patients, respectively. The trend toward faster sputum conversion (by culture) and healing of cavities persisted throughout the study period in CT+ST Group versus CT Group. In the patients from cavernous and fibrous cavernous tuberculosis subgroup of CT+ST Group, cavities healed more frequently (size up to 3 cm) by week 8 of treatment versus the same subgroup of CT Group. No serious adverse reactions were observed during the study, and no connection between adverse reactions and the use of tauractant was established.

  • Open Access

    Effectiveness and Safety of Short-Course Chemotherapy Regimens for Drug-Resistant Tuberculosis: Literature Review and Meta-Analysis

    by A. V. Abramchenko, M. I. Romanova, A. I. Gayda, G. N. Mozhokina, A. G. Samoylova, I. A. Vasilyeva

    The objective: to evaluate clinical effectiveness and safety of short-course chemotherapy regimens in patients with drug-resistant tuberculosis based on a systematic and meta-analytic study.Subjects and Methods. A systematic search for scientific publications published between 01.01.2018 and 01.10.2023 was conducted in PubMed and eLibrary. Sixty-six studies were selected using the keywords “treatment of drug-resistant tuberculosis, randomized clinical trials”. By a manual review, 7 publications meeting required parameters for meta-analysis were identified.Results. A single-group meta-analysis of the effectiveness of short-term chemotherapy regimens demonstrated the following: a favorable outcome can be achieved in 80.9% of cases; an unfavorable outcome occurs in 19.4%; sputum culture conversion by 8 weeks of chemotherapy is achieved in 74.6% of cases; SAEs were registered in 15.1% of patients, grade 3 and higher SAEs- in 39.5% (based on 4 publications).


  • Open Access

    Treatment Results in Patients with Drug Resistant Tuberculosis (MDR, pre-XDR, XDR) and HIV Infection in Stavropol Region

    by N. A. Sosova, T. A. Zadremaylova, N. M. Konovalova, A. V. Abramchenko, M. I. Romanova, A. I. Gayda, A. G. Samoylova

    The objective: to compare treatment effectiveness of drug resistant tuberculosis (MDR, pre-XDR, XDR) depending on the HIV status of patients in Stavropol Region from 2019 to 2022.Subjects and Methods. In a retrospective study, chemotherapy outcomes for pulmonary tuberculosis (TB) were evaluated with distribution by treatment regimens for MDR, pre-XDR, and XDR in 100 patients with drug resistant tuberculosis (MDR, pre-XDR, XDR and HIV infection (DR TB/HIV Group ) and 707 patients with drug resistant tuberculosis (MDR, pre-XDR, and XDR) (and negative HIV status (DR TB Group). The immune status of patients in DR TB/HIV Group and its impact on the effectiveness of tuberculosis treatment were analyzed.Results. Effective treatment (definitions are given according to the Guidelines) was statistically significantly more frequently registered in DR TB Group versus DR TB/HIV Group (59% and 48%, respectively, p<0.05). Treatment failure was statistically significantly more frequently registered in patients in DR TB/HIV Group versus DR TB Group (42% and 26%, respectively, p<0.05). In DR TB/HIV Group, the lowest effectiveness (33%) of tuberculosis treatment was noted in the patients with CD4 count below 200 cells/µL. Among those died, the median time to death from the start of tuberculosis treatment was 12 months in DR TB Group, 8 months in DR TB/HIV Group, and 4 months in the subgroup of patients with CD4 count below 100 cells/µL.


  • Open Access

    Efficacy of Interferon-γ (Ingaron) Against Tuberculosis in BALB/c Mouse Mode

    by Irina A Vasileva, Anastasia G Samoilova, Anna V Abramchenko, Vadim V Avdeev, Anatoliy S Vinokurov, Maria Ya Romanova, Svetlana I Kayukova

    Interferon-gamma (IFN-γ) is an important cytokine in host defense against tuberculosis infection. In some cases, administration of IFN-γ during tuberculosis infection can promote faster cure. In the present work, we have shown that in a mouse model, human interferon-gamma, exhibits some anti-tuberculosis activity, especially in combination with isoniazid.


  • Open Access

    Effectiveness of Surgical Treatment of Patients with Destructive Pulmonary Tuberculosis (Meta-Analysis)

    by M. I. Romanova, A. I. Gayda, A. V. Abramchenko, G. N. Mozhokina, O. V. Lovacheva

    The objective: to study effectiveness of surgical methods for treatment of various forms of destructive pulmonary tuberculosis (meta-analysis).Subjects and Methods. A systematic search was performed in electronic bibliographic databases, including PubMed and Google Scholar. Cohort studies published from January 1, 2019 to June 20, 2023 were selected, those studies were aimed to assess effectiveness of surgical treatment in patients with destructive tuberculosis using resections of various volume. For meta-analysis, 9 studies published in 2019 - 2023 were selected.Results. The effectiveness of comprehensive treatment with resections of various volume in destructive pulmonary tuberculosis patients made 85.3%. The success of surgical treatment in patients with fibrous cavernous pulmonary tuberculosis was somewhat less – 80.3%. At the same time, the incidence of postoperative complications in patients with fibrous cavernous pulmonary tuberculosis was higher and could reach 42.5%, while in the group patients with destructive tuberculosis, it was 27.3%. Some postoperative complications required repeated operations. The ratio of surgeries to patients was the following: 3263 surgical interventions per 1564 patients (average 2.08 surgeries per patient). Hospital lethality among patients with fibrous cavernous pulmonary tuberculosis after surgical treatment was 2.6%, and tuberculosis mortality within 5 years after surgery was 4.8%. The relapse rate among patients with fibrous cavernous pulmonary tuberculosis after surgical treatment was 7.1%.


  • Open Access

    Clinical Efficacy and Safety of Clofazimine in Treatment Regimens for Drug Resistant Tuberculosis (Meta-Analysis)

    by A. I. Gayda, A. V. Abramchenko, M. I. Romanova, G. N. Mozhokina, A. G. Samoylova, I. A. Vasilyeva

    The objective: based on a systematic review and meta-analysis of data from published results of clinical studies, to evaluate clinical efficacy and safety of chemotherapy regimens containing clofazimine in MDR-TB patients.Subjects and Methods. A systematic analysis of publications was performed using key words “clofazimine”, “tuberculosis treatment”, “mycobacteria drug resistance”, and “safety” in electronic libraries: PubMed, Google Scholar, eLIBRARY.RU, and medRvix. 7 clinical studies were selected for further analysis.Results. The risk of treatment failure in main groups receiving regimens containing clofazimine was 1.7 times lower versus control groups (without clofazimine) (p = 0.02; RR = 0.6 (95% CI: 0.39 – 0.92)). The risk of sputum conversion by week 12 of treatment is 7 times higher in main groups receiving regimens containing clofazimine versus control groups (p = 0.01; RR = 0.14 (95% CI: 0.03 – 0.25)). The risk of adverse events in main groups receiving regimens containing clofazimine was comparable to control groups (p = 0.54; RR = 1.27 (95% CI: 0.59 – 2.71)).